By Kevin A. Wilson, theaestheticguide.com

When thinking about radiofrequency (RF) based aesthetic treatments, one typically conjures a ‘surface downward’ paradigm. However, there may be a significant advantage to approaching the challenge from within rather than from the outside in.

Supported by eight years of research, Attiva from Reveal Lasers, LLC (Las Vegas, Nev.) is designed for single-treatment stimulation of new collagen and elastin – with improved microcirculation – via mini-cannula-delivered RF for subdermal coagulation of skin of the face and body. The technology is called iRF (intelligent radiofrequency), referring to its combination of RF with temperature sensing and control mechanisms. This minimally invasive endodermal approach uses proprietary RF delivery mechanisms, and is enhanced with safety and energy management features designed to optimize comfort and energy delivery for best results. It can treat a range of indications from the eyebrows to the thighs and, best of all, there is no scarring or downtime.

Jack Zamora, MD, a plastic surgeon in Denver, Colo., believes that Attiva’s simple, no downtime treatment, combined with its unique capabilities, has transformed the way his practice approaches anti-aging therapies. “The firmness of the tissue caused by the subdermal coagulation is immediately visible to the patient and practitioner. Understanding that Attiva stimulates fibroblasts gives us high expectations for the quality and duration of the effects of this proprietary energy,” he elaborated.

“Instead of the common single 1 MHz frequency seen in most RF devices, Attiva utilizes a combination of multiple RF wavelengths,” he added. The full result, which depends on the generation of new collagen and elastin over time, manifests over the two to three months following the procedure. Optimal results take about three to five months, and changes should persist beyond 18 months. “I think this device may become ubiquitous because it does what it does so well.”

Attiva relies on disposable mini cannulas of varying length and gauge (length: 5 cm, 10 cm, 15 cm, or 20 cm; from 22G to 16G); each with an incorporated electrode to address different areas of the face and body. The rationale behind this endodermal approach is to maximize tissue interaction with the energy. There is also an ancillary mechanical effect from subcutaneous stimulation of structural cells affected by the thermoelectric stimulus. Localized stimulation of angiogenesis improves both capillary and arteriolar microcirculation as well, essential for healing and persistence of results.

Double Temperature Control, referring to the real time feedback loop created by the temperature sensors in the cannula, “helps keep treatment temperature significantly below the typical 65° C or 85° C temperatures that other endodermal RF devices need to reach before achieving their therapeutic effects,” Dr. Zamora explained. “This places Attiva among the top of all endodermal RF technologies with respect to safety.”

According to Dr. Zamora, it safely bridges the gap between injectables and surgery for the face and body. “Almost every medspa relies on external or RF microneedling devices. Because Attiva sends the energy deeper, in a minimally invasive way, it organically fills the space between surgery and minimally invasive or injectables-based therapies. Further study to fully develop the technology’s potential is ongoing,” he shared.

“Reveal is also doing an exceptional job at delivering the highest quality training and support for customers of the device,” Dr. Zamora added. Reveal Lasers’ boutique marketing support includes highly trained practice development managers who stand beside device owners during the entire process, from onboarding and installation to training, marketing, event planning, and beyond.